{'fraction_non_alphanumeric': 0.020066889632107024, 'fraction_numerical': 0.0, 'mean_word_length': 5.655555555555556, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CAR T‐cell therapy‐related neurotoxicity in paediatric acute lymphocytic leukaemia

The advent of chimeric antigen receptor (CAR) T‐cell therapy has created a paradigm shift in the management of patients with refractory B‐cell acute lymphocytic leukaemia (ALL). The aim of this study is to correlate imaging findings of CAR T‐cell therapy related neurotoxicity with clinical course and eventual clinical outcome, with the hope that it will bring us a step closer to the identification of potential imaging biomarkers that may allow more accurate prognostication and risk stratification of patients.